openPR Logo
Press release

CIGB’s researchers defeat cancer once again

09-14-2018 09:27 AM CET | Health & Medicine

Press release from: Center for Genetic Engineering and Biotechnology

HeberFERON research staff

HeberFERON research staff

Havana – September 13, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce favorable results of an innovative medicine developed by Cuban researchers and engineers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with the trademark HeberFERON® (J. Cancer Res. Ther. 2013, 1 (10): 235-243).

HeberFERON® has shown consistent results in clinical trials after extensive pre-clinical investigations. In several clinical trials (Open prospective trial, phase II double-blind randomized studies, retrospective study and ongoing phase IV) more than 200 patients with histological diagnostic of non-melanoma skin cancer were recruited to be treated with HeberFERON® in Cuban institutions at primary, secondary or tertiary health care levels. The open-label prospective study showed 46.7% complete response in locally advanced basal-cell carcinoma of the skin after application of HeberFERON®. Patients with periocular basal-cell carcinoma or squamous cell skin carcinomas received benefits from HeberFERON® treatment (71.4% objective response). HeberFERON® has been administered to patients with non-melanoma skin cancer obtaining a 65% of histological complete response together with an excellent safety profile (BMC Cancer 2009, 9:262; Aust. Med. J. 2017, 10 (6): 509-515; J. Clin. Exp. Ophthalmol. 2015, 6: 5).

A national program for extending the use of HeberFERON ® has successfully been implemented in Cuba from 2016 with intensive participation of CIGB’s researchers, 430 medical doctors (241 dermatologists, 57 maxillofacial surgeon, 23 ophthalmologists, 37 oncologists, 10 aesthetic surgeon, 4 MGI), 36 nurses, and 22 students of medicine all over the country. A total of 182 mutilations were avoided (52.4%). 90 patients were saved from nose mutilations, 37 from ear mutilations, 35 eyelid mutilations, and 20 from other mutilations. In 2017, a total of 590 patients were treated with HeberFERON® to obtain an objective response of 86.4%. This year, 830 patients have been treated until now to obtain an objective response of 94.7%.

Contact:
Osvaldo Reyes Acosta, Eng., MSc.
Center for Genetic Engineering and Biotechnology (CIGB)
Ave 31 e/ 158 y 190, Playa, P.O.
Box 6162, Habana 10600, Cuba
Tel: 7 250 4644.
e-mail: osvaldo.reyes@cigb.edu.cu
Written by: José A. Buxadó, Eng., MSc., and Náyade Beltrán, BSc.
Photo: Yutdelis Roben Aguiar, BSc.

The Center for Genetic Engineering and Biotechnology is a Cuban institution devoted to research, development, and commercialization of products and technologies. This institution has developed vaccines, therapeutics, and agricultural technologies to penetrate local and foreign markets in more than 50 countries during 32 years.

Center for Genetic Engineering and Biotechnology (CIGB)
Ave 31 e/ 158 y 190, Playa, P.O.
Box 6162, Habana 10600, Cuba
Tel: 7 250 4644.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CIGB’s researchers defeat cancer once again here

News-ID: 1238200 • Views: 214

More Releases from Center for Genetic Engineering and Biotechnology

Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with
President of India visits CIGB today to reinforce bilateral trade and scientific …
Havana, June 22nd, 2018 - The 14th and current President of India, in office since July 25th 2017, Ram Nath Kovind (b. 1945) visited the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. President Ram Nath Kovind was received by the President of BioCubaFarma, Dr. Eduardo Martínez, and the General Director of the CIGB Dr. Eulogio Pimentel. This is a very important date in the agenda of Mr.
Approval for commercialization of Heberprot-P® in Mexico
Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing

All 4 Releases


More Releases for HeberFERON

Researchers defeat cancer once again
Havana, September 17, 2018. The Center for Genetic Engineering and Biotechnology (CIGB) is pleased to announce positive outcomes of an innovative medicine developed by CIGB's researchers intended to inhibit growth of tumor cell lines representative of basal-cell carcinoma of the skin, and malignant gliomas. This new medicine, designed as a synergic combination of recombinant human interferons alpha 2b and gamma, has been approved for commercialization in Cuba, and registered with